Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30. doi: 10.3322/caac.21442.
   Google Scholar
• Hontscha C, Borck Y, Zhou H, Messmer D, Schmidtwolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305–310. doi:10.1007/s00432-010-0887-7.
   PubMed Web of Science ®Google Scholar
• Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF, Qiu JG. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J. 2012;125:3771–3777. doi:10.3760/cma.j.issn.0366-6999.2012.21.004.
   PubMed Web of Science ®Google Scholar
• Anichini A, Tassi E, Grazia G, Mortarini R. The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunol Immunother. 2018;67:1011–1022. doi:10.1007/s00262-018-2147-7.
   PubMed Web of Science ®Google Scholar
• Introna M, Correnti F. Innovative clinical perspectives for CIK cells in cancer patients. Int J Mol Sci. 2018:19. doi:10.3390/ijms19020358.
   Web of Science ®Google Scholar
• Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C, Foddai ML, Lorusso D, Martinelli E, Vacca M. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy. 2012;14:841–850. doi:10.3109/14653249.2012.681038.
   PubMed Web of Science ®Google Scholar
• Chu H, Du F, Jiang L, Wang Z, Gong Z, Lian P, Li P, Chen J. The efficacy of CIK-based immunotherapies for advanced solid tumors. Technol Cancer Res Treat. 2017;16:577–585. doi:10.1177/1533034616659163.
   PubMed Web of Science ®Google Scholar
• Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, Su N, Ma Y, Li X, Sun S, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: from preparation and testing to clinical application. Hum Vaccin Immunother. 2017;13:1–9. doi:10.1080/21645515.2017.1285987.
   Web of Science ®Google Scholar
• Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673–684. doi:10.1517/14712598.2012.675323.
   PubMed Web of Science ®Google Scholar
• Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, Wu C. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61:2251–2259. doi:10.1007/s00262-012-1289-2.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu L, Wei J, Liu L, Yin Y, Gu Y, Shu Y. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol. 2012;138:1057–1062. doi:10.1007/s00432-012-1179-1.
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Chang D, Lv D, Li H, Zhang H. Clinical value of Pro-GRP and T lymphocyte subpopulation for the assessment of immune functions of lung cancer patients after DC-CIK biological therapy. Exp Ther Med. 2018;15:1580–1585. doi:10.3892/etm.2017.5520.
   PubMed Web of Science ®Google Scholar
• Song H, Liu S, Zhao Z, Sun W, Wei X, Ma X, Zhao P, Gao D. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC. Int Immunopharmacol. 2017;52:197–202. doi:10.1016/j.intimp.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018:1–9. doi:10.1080/15384047.2018.1433501.
   Web of Science ®Google Scholar
• Zhang X, Du M, Zhang Q, Chen H, Zhao L, Li H, Guo W. In vivo anti-tumor effect of DC-CIK cells on human lymphoma cell line Raji. Pak J Pharm Sci. 2017;30:1075–1079.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yun MM, Dong X, Xu M, Zhao R, Han X, Zhou E, Yun F, Su W, Liu C. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. Cytotherapy. 2015;18:91. doi:10.1016/j.jcyt.2015.09.012.
   Web of Science ®Google Scholar
• Zou Y, Li F, Hou W, Sampath P, Zhang Y, Thorne SH. Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells. Br J Cancer. 2014;110:1992. doi:10.1038/bjc.2014.140.
   PubMed Web of Science ®Google Scholar
• Li QY, Shi Y, Huang DH, Yang T, Wang JH, Yan GH, Wang HY, Tang XJ, Xiao CY, Zhang WJ, et al. Cytokine-induced killer cells combined with dendritic cells inhibited liver cancer cells. Int J Clin Exp Med. 2015;8:5601–5610.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L, Jin H, Qian Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol. 2015;4:32. doi:10.1186/s40164-015-0027-9.
   PubMedGoogle Scholar
• Zhao X, Ji C-Y, Liu G-Q, Ma D-X, Ding H-F, Xu M, Xing J. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol. 2015;8:13146.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng Z, Zhang Q, Zhou X, Feng Y, Yan A. FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis. Onco Targets Ther. 2017;10:2621–2633. doi:10.2147/ott.s138011.
   PubMed Web of Science ®Google Scholar
• Sun WW, Dou JX, Zhang L, Qiao LK, Shen N, Zhao Q, Gao WY. Killing effects of Huaier Granule combined with DC-CIK on nude mice transplanted with colon carcinoma cell line. Oncotarget. 2017;8:46081–46089. doi:10.18632/oncotarget.17687.
   PubMedGoogle Scholar
• Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160–4167. doi:10.1158/1078-0432.CCR-05-0120.
   PubMed Web of Science ®Google Scholar
• Dong B, Wang A, Yuan L, Chen L, Pu K, Duan W, Yan X, Zhu Y. Peptide-fluorescent bacteria complex as luminescent reagents for cancer diagnosis. PLoS One. 2013;8:e54467. doi:10.1371/journal.pone.0054467.
   PubMed Web of Science ®Google Scholar
• Wang A, Chen L, Pu K, Zhu Y. Identification of stem-like cells in non-small cell lung cancer cells with specific peptides. Cancer Lett. 2014;351:100–107. doi:10.1016/j.canlet.2014.05.004.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, Pu K, Zhu Y. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy. Cancer Immunol Res. 2018;6:178–188. doi:10.1158/2326-6066.cir-17-0035.
   PubMed Web of Science ®Google Scholar
• Ott PA. Immunotherapy: immune-modified response criteria - an iterative learning process? Nat Rev Clin Oncol. 2018. doi:10.1038/nrclinonc.2018.36.
   PubMed Web of Science ®Google Scholar
• Seya T, Takeda Y, Takashima K, Yoshida S, Azuma M, Matsumoto M. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94:153–160. doi:10.2183/pjab.94.011.
   PubMed Web of Science ®Google Scholar
• Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2017;12:Cd011300. doi:10.1002/14651858.CD011300.pub2.
   PubMedGoogle Scholar
• Cheng XY, Li JL. Biological activity of cytotoxic dendritic cells cocultured with cytokine-induced killer cells and their effect on acute leukemia cells. Genet Mol Res. 2015;14:13208–13214. doi:10.4238/2015.October.26.17.
   PubMed Web of Science ®Google Scholar
• Li SJ, Zhang LS, Chai Y, Zhang YF, Zhang YM, Zeng PY, Wu CY. Killing activity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines. Zhonghua Zhong Liu Za Zhi. 2007;29:733–737.
   PubMedGoogle Scholar
• Liu Y, Liu H, Liu H, He P, Li J, Liu X, Chen L, Wang M, Xi J, Wang H, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett. 2016;12:5205–5210. doi:10.3892/ol.2016.5337.
   PubMed Web of Science ®Google Scholar
• Shan CC, Shi LR, Ding MQ, Zhu YB, Li XD, Xu B, Jiang JT, Wu CP. Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. Oncol Lett. 2015;9:1549–1556. doi:10.3892/ol.2015.2977.
   PubMed Web of Science ®Google Scholar
• Clark GJ, Silveira PA, Hogarth PM, Hart DNJ. The cell surface phenotype of human dendritic cells. Semin Cell Dev Biol. 2018. doi:10.1016/j.semcdb.2018.02.013.
   PubMed Web of Science ®Google Scholar
• Ivanov S, Merlin J, Lee MKS, Murphy AJ, Guinamard RR. Biology and function of adipose tissue macrophages, dendritic cells and B cells. Atherosclerosis. 2018;271:102–110. doi:10.1016/j.atherosclerosis.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, Ishii J, Ito M, Akatsuka Y, Kuzushima K, Yoshida J. Identification of a human leukocyte antigen-A24–restricted T-cell epitope derived from interleukin-13 receptor α2 chain, a glioma-associated antigen. J Neurosurg. 2008;109:117–122. doi:10.3171/JNS/2008/109/7/0117.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xu Y-C, Tang L, Zhang Z, Wang J, Wang H-X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1:11. doi:10.1186/2162-3619-1-11.
   PubMedGoogle Scholar
• Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, et al. Chimeric antigen receptor T-cell therapy. J Natl Compr Canc Netw. 2018;16:1093–1106. doi:10.6004/jnccn.2018.0073.
   Web of Science ®Google Scholar
• Zou WP. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307. doi:10.1038/nri1806.
   PubMed Web of Science ®Google Scholar